vs
Side-by-side financial comparison of Bausch & Lomb Corp (BLCO) and First Solar (FSLR). Click either name above to swap in a different company.
Bausch & Lomb Corp is the larger business by last-quarter revenue ($1.4B vs $1.0B, roughly 1.3× First Solar). First Solar runs the higher net margin — 33.2% vs -4.1%, a 37.3% gap on every dollar of revenue. On growth, First Solar posted the faster year-over-year revenue change (23.6% vs 9.8%). Over the past eight quarters, Bausch & Lomb Corp's revenue compounded faster (13.1% CAGR vs 1.7%).
Bausch & Lomb is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb. Until its sale in 2013, Bausch + Lomb was one of the oldest continually operating companies in the United States.
First Solar, Inc. is a publicly traded American manufacturer of solar panels. First Solar uses rigid thin-film modules for its solar panels, and produces CdTe panels using cadmium telluride (CdTe) as a semiconductor. The company was founded in 1990 by inventor Harold McMaster as Solar Cells, Inc. In 1999 it was purchased by True North Partners, LLC, which rebranded it as First Solar, Inc. It provides end-of-life panel recycling at each of its manufacturing facilities.
BLCO vs FSLR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $1.0B |
| Net Profit | $-58.0M | $346.6M |
| Gross Margin | — | 46.6% |
| Operating Margin | 8.0% | 33.1% |
| Net Margin | -4.1% | 33.2% |
| Revenue YoY | 9.8% | 23.6% |
| Net Profit YoY | -1833.3% | 65.4% |
| EPS (diluted) | $-0.16 | $3.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.0B | ||
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.3B | $1.6B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $1.1B | $844.6M | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.2B | $887.7M | ||
| Q2 24 | $1.2B | $1.0B |
| Q1 26 | — | $346.6M | ||
| Q4 25 | $-58.0M | $520.9M | ||
| Q3 25 | $-28.0M | $455.9M | ||
| Q2 25 | $-62.0M | $341.9M | ||
| Q1 25 | $-212.0M | $209.5M | ||
| Q4 24 | $-3.0M | $393.1M | ||
| Q3 24 | $4.0M | $313.0M | ||
| Q2 24 | $-151.0M | $349.4M |
| Q1 26 | — | 46.6% | ||
| Q4 25 | — | 39.5% | ||
| Q3 25 | — | 38.3% | ||
| Q2 25 | — | 45.6% | ||
| Q1 25 | — | 40.8% | ||
| Q4 24 | — | 37.5% | ||
| Q3 24 | — | 50.2% | ||
| Q2 24 | — | 49.4% |
| Q1 26 | — | 33.1% | ||
| Q4 25 | 8.0% | 32.6% | ||
| Q3 25 | 7.4% | 29.2% | ||
| Q2 25 | -0.9% | 33.0% | ||
| Q1 25 | -7.3% | 26.2% | ||
| Q4 24 | 6.8% | 30.2% | ||
| Q3 24 | 3.6% | 36.3% | ||
| Q2 24 | 2.1% | 36.9% |
| Q1 26 | — | 33.2% | ||
| Q4 25 | -4.1% | 31.0% | ||
| Q3 25 | -2.2% | 28.6% | ||
| Q2 25 | -4.9% | 31.2% | ||
| Q1 25 | -18.6% | 24.8% | ||
| Q4 24 | -0.2% | 26.0% | ||
| Q3 24 | 0.3% | 35.3% | ||
| Q2 24 | -12.4% | 34.6% |
| Q1 26 | — | $3.22 | ||
| Q4 25 | $-0.16 | $4.84 | ||
| Q3 25 | $-0.08 | $4.24 | ||
| Q2 25 | $-0.18 | $3.18 | ||
| Q1 25 | $-0.60 | $1.95 | ||
| Q4 24 | $-0.00 | $3.66 | ||
| Q3 24 | $0.01 | $2.91 | ||
| Q2 24 | $-0.43 | $3.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $383.0M | $2.4B |
| Total DebtLower is stronger | $5.0B | $425.8M |
| Stockholders' EquityBook value | $6.4B | $9.9B |
| Total Assets | $14.0B | $13.4B |
| Debt / EquityLower = less leverage | 0.78× | 0.04× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.4B | ||
| Q4 25 | $383.0M | $2.8B | ||
| Q3 25 | $310.0M | $2.0B | ||
| Q2 25 | $266.0M | $1.1B | ||
| Q1 25 | $202.0M | $837.6M | ||
| Q4 24 | $305.0M | $1.6B | ||
| Q3 24 | $329.0M | $1.0B | ||
| Q2 24 | $285.0M | $1.7B |
| Q1 26 | — | $425.8M | ||
| Q4 25 | $5.0B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — |
| Q1 26 | — | $9.9B | ||
| Q4 25 | $6.4B | $9.5B | ||
| Q3 25 | $6.4B | $9.0B | ||
| Q2 25 | $6.4B | $8.5B | ||
| Q1 25 | $6.4B | $8.2B | ||
| Q4 24 | $6.5B | $8.0B | ||
| Q3 24 | $6.6B | $7.6B | ||
| Q2 24 | $6.5B | $7.3B |
| Q1 26 | — | $13.4B | ||
| Q4 25 | $14.0B | $13.3B | ||
| Q3 25 | $13.8B | $13.5B | ||
| Q2 25 | $13.8B | $12.9B | ||
| Q1 25 | $13.4B | $12.1B | ||
| Q4 24 | $13.5B | $12.1B | ||
| Q3 24 | $13.5B | $11.4B | ||
| Q2 24 | $13.3B | $11.0B |
| Q1 26 | — | 0.04× | ||
| Q4 25 | 0.78× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.76× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $136.0M | $-214.9M |
| Free Cash FlowOCF − Capex | $60.0M | — |
| FCF MarginFCF / Revenue | 4.3% | — |
| Capex IntensityCapex / Revenue | 5.4% | — |
| Cash ConversionOCF / Net Profit | — | -0.62× |
| TTM Free Cash FlowTrailing 4 quarters | $-66.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-214.9M | ||
| Q4 25 | $136.0M | $1.2B | ||
| Q3 25 | $137.0M | $1.3B | ||
| Q2 25 | $35.0M | $149.6M | ||
| Q1 25 | $-25.0M | $-608.0M | ||
| Q4 24 | $22.0M | $811.0M | ||
| Q3 24 | $154.0M | $-53.7M | ||
| Q2 24 | $15.0M | $193.0M |
| Q1 26 | — | — | ||
| Q4 25 | $60.0M | $1.1B | ||
| Q3 25 | $63.0M | $1.1B | ||
| Q2 25 | $-54.0M | $-138.6M | ||
| Q1 25 | $-135.0M | $-813.9M | ||
| Q4 24 | $-70.0M | $497.5M | ||
| Q3 24 | $94.0M | $-487.7M | ||
| Q2 24 | $-57.0M | $-172.1M |
| Q1 26 | — | — | ||
| Q4 25 | 4.3% | 63.6% | ||
| Q3 25 | 4.9% | 67.1% | ||
| Q2 25 | -4.2% | -12.6% | ||
| Q1 25 | -11.9% | -96.4% | ||
| Q4 24 | -5.5% | 32.9% | ||
| Q3 24 | 7.9% | -54.9% | ||
| Q2 24 | -4.7% | -17.0% |
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | 10.2% | ||
| Q3 25 | 5.8% | 12.8% | ||
| Q2 25 | 7.0% | 26.3% | ||
| Q1 25 | 9.7% | 24.4% | ||
| Q4 24 | 7.2% | 20.7% | ||
| Q3 24 | 5.0% | 48.9% | ||
| Q2 24 | 5.9% | 36.1% |
| Q1 26 | — | -0.62× | ||
| Q4 25 | — | 2.38× | ||
| Q3 25 | — | 2.79× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | -2.90× | ||
| Q4 24 | — | 2.06× | ||
| Q3 24 | 38.50× | -0.17× | ||
| Q2 24 | — | 0.55× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
FSLR
Segment breakdown not available.
